AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2

B. N. Fahy, M. Schlieman, S. Virudachalam, Richard J Bold

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Activation of the serine/threonine kinase AKT is common in pancreatic cancer, inhibition of which sensitises cells to the apoptotic effect of chemotherapy. Of the various downstream targets of AKT, we examined activation of the NF-κB transcription factor and subsequent transcriptional regulation of BCL-2 gene family in pancreatic cancer cells. Inhibition of either phosphatidylinositol-3 kinase or AKT led to a decreased protein level of the antiapoptotic gene BCL-2 and an increased protein level of the proapoptotic gene BAX. Furthermore, inhibition of AKT decreased the function of NF-κB, which is capable of transcriptional regulation of the BCL-2 gene. Inhibiting this pathway had little effect on the basal level of apoptosis in pancreatic cancer cells, but increased the apoptotic effect of chemotherapy. The antiapoptotic effect of AKT activation in pancreatic cancer cells may involve transcriptional induction of a profile of BCL-2 proteins that confer resistance to apoptosis; alteration of this balance allows sensitisation to the apoptotic effect of chemotherapy.

Original languageEnglish (US)
Pages (from-to)391-397
Number of pages7
JournalBritish Journal of Cancer
Volume89
Issue number2
DOIs
StatePublished - Jul 21 2003

Fingerprint

Pancreatic Neoplasms
Cell Line
Drug Therapy
Genes
Phosphatidylinositol 3-Kinase
Apoptosis
Proteins
Protein-Serine-Threonine Kinases
Transcription Factors

Keywords

  • AKT
  • BCL-2
  • NF-κB
  • Pancreas cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. / Fahy, B. N.; Schlieman, M.; Virudachalam, S.; Bold, Richard J.

In: British Journal of Cancer, Vol. 89, No. 2, 21.07.2003, p. 391-397.

Research output: Contribution to journalArticle

@article{4a6e27d09df643eb9a7112869a121006,
title = "AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2",
abstract = "Activation of the serine/threonine kinase AKT is common in pancreatic cancer, inhibition of which sensitises cells to the apoptotic effect of chemotherapy. Of the various downstream targets of AKT, we examined activation of the NF-κB transcription factor and subsequent transcriptional regulation of BCL-2 gene family in pancreatic cancer cells. Inhibition of either phosphatidylinositol-3 kinase or AKT led to a decreased protein level of the antiapoptotic gene BCL-2 and an increased protein level of the proapoptotic gene BAX. Furthermore, inhibition of AKT decreased the function of NF-κB, which is capable of transcriptional regulation of the BCL-2 gene. Inhibiting this pathway had little effect on the basal level of apoptosis in pancreatic cancer cells, but increased the apoptotic effect of chemotherapy. The antiapoptotic effect of AKT activation in pancreatic cancer cells may involve transcriptional induction of a profile of BCL-2 proteins that confer resistance to apoptosis; alteration of this balance allows sensitisation to the apoptotic effect of chemotherapy.",
keywords = "AKT, BCL-2, NF-κB, Pancreas cancer",
author = "Fahy, {B. N.} and M. Schlieman and S. Virudachalam and Bold, {Richard J}",
year = "2003",
month = "7",
day = "21",
doi = "10.1038/sj.bjc.6601037",
language = "English (US)",
volume = "89",
pages = "391--397",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2

AU - Fahy, B. N.

AU - Schlieman, M.

AU - Virudachalam, S.

AU - Bold, Richard J

PY - 2003/7/21

Y1 - 2003/7/21

N2 - Activation of the serine/threonine kinase AKT is common in pancreatic cancer, inhibition of which sensitises cells to the apoptotic effect of chemotherapy. Of the various downstream targets of AKT, we examined activation of the NF-κB transcription factor and subsequent transcriptional regulation of BCL-2 gene family in pancreatic cancer cells. Inhibition of either phosphatidylinositol-3 kinase or AKT led to a decreased protein level of the antiapoptotic gene BCL-2 and an increased protein level of the proapoptotic gene BAX. Furthermore, inhibition of AKT decreased the function of NF-κB, which is capable of transcriptional regulation of the BCL-2 gene. Inhibiting this pathway had little effect on the basal level of apoptosis in pancreatic cancer cells, but increased the apoptotic effect of chemotherapy. The antiapoptotic effect of AKT activation in pancreatic cancer cells may involve transcriptional induction of a profile of BCL-2 proteins that confer resistance to apoptosis; alteration of this balance allows sensitisation to the apoptotic effect of chemotherapy.

AB - Activation of the serine/threonine kinase AKT is common in pancreatic cancer, inhibition of which sensitises cells to the apoptotic effect of chemotherapy. Of the various downstream targets of AKT, we examined activation of the NF-κB transcription factor and subsequent transcriptional regulation of BCL-2 gene family in pancreatic cancer cells. Inhibition of either phosphatidylinositol-3 kinase or AKT led to a decreased protein level of the antiapoptotic gene BCL-2 and an increased protein level of the proapoptotic gene BAX. Furthermore, inhibition of AKT decreased the function of NF-κB, which is capable of transcriptional regulation of the BCL-2 gene. Inhibiting this pathway had little effect on the basal level of apoptosis in pancreatic cancer cells, but increased the apoptotic effect of chemotherapy. The antiapoptotic effect of AKT activation in pancreatic cancer cells may involve transcriptional induction of a profile of BCL-2 proteins that confer resistance to apoptosis; alteration of this balance allows sensitisation to the apoptotic effect of chemotherapy.

KW - AKT

KW - BCL-2

KW - NF-κB

KW - Pancreas cancer

UR - http://www.scopus.com/inward/record.url?scp=0043122940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043122940&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601037

DO - 10.1038/sj.bjc.6601037

M3 - Article

C2 - 12865934

AN - SCOPUS:0043122940

VL - 89

SP - 391

EP - 397

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -